Connect with us

Hi, what are you looking for?

Thursday, Oct 21, 2021
Mugglehead Magazine
Cannabis & psychedelics industry news based in Vancouver, B.C.
  • Loading stock data...

Business

Tilray moves to take large stake in US retailer MedMen

Tilray will exchange 9 million shares for a potential 21% stake

Employees examining cannabis plant at Tilray facility
Image via Tilray

A deal by Tilray, Inc. (TSX: TLRY) (Nasdaq: TLRY) to acquire a significant stake in a leading American cannabis retail brand signals more aggressive moves by the Canadian weed giant to cement its presence south of the border.

On Tuesday, in a partnership with other investors, Tilray said it acquired the majority of the outstanding senior secured convertible notes of MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) worth about US$165.8 million. The notes were originally held by LLC Gotham Green Partners (GPP).

Tilray will exchange about nine million of its shares to GGP.

As a result, Tilray could have around a 21 per cent stake in MedMen through the conversion of notes into equity following cannabis legalization in the U.S., or sooner if Tilray chooses to waive that condition.

If Tilray hasn’t been given stockholder approval by Dec. 1, 2021, GGP can opt for cash instead of Tilray shares.

MedMen has 25 U.S. locations in major cities like L.A. Boston, Chicago, and Las Vegas as well as a significant position in California, the world’s largest weed market.

MedMen was once considered one of the most valuable U.S. retailers, but the high didn’t last long and the company’s leadership has been sharply criticized.

In 2018, the company was valued in the billions, but it soon fell drastically after reporting steep losses and hefty payouts to top management.

Read more: Execs shouldn’t get big payouts until companies are cash flow positive: Ryerson prof

Read more: Tilray 1.0 quietly discloses first-quarter US$341M loss

While its share price was soaring at the end of 2018 at a high of $8.50 a share on Oct. 19, financial woes amplified over 2019 and MedMen’s valuation steadily dropped to where it sits today at $0.34 a share and a market cap of just $234.72 million.

Tilray’s stock is up 0.3 per cent to $16.53 on the Nasdaq.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Kathryn Tindale on Twitter

kathryn@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can

Canada

As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices

Analysis

While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe

Culture

Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance